Heart Damage Articles & Analysis
29 news found
The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. ...
High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...
The investigational gene therapy is administered directly to the heart muscle through a mini-thoracotomy by an experienced cardiac surgeon. ...
High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...
Already at an early stage of the disease, patients suffer from episodes of impaired blood flow in the fingers and toes, Raynaud's phenomenon, which in the course of the disease often lead to very painful, difficult-to-heal, and frequently disabling ulcers. The lungs, kidneys and heart can also be seriously damaged due to inflammation and damage ...
If the blocked blood vessel is pierced with a fine wire mesh, a large amount of blood is supplied to the stopped heart. When this happens, the amount of free radicals suddenly increases and the heart muscle is damaged. Bilirubin, which has an antioxidant effect, removes free radicals and minimizes damage to the ...
XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, has an exclusive license from Cornell ...
Over €100 bn euros, or 50% of the total European healthcare budget is spent treating patients with heart diseases. The EIC accelerator was established to support individual start-ups and small companies to develop and scale up game changing innovations. With the EIC support this funding will enable Genome Biologics to accelerate development of its clinical programmes, ...
About XC001 XC001 is an investigational gene therapy designed to promote the growth of new blood vessels in the heart, with these new blood vessels bypassing diseased blood vessels and improving blood flow in the heart. XC001 deposits the gene for vascular endothelial growth factor (VEGF) in targeted heart cells. VEGF is a naturally occurring ...
Unfortunately, delays in treatment can lead to a host of catastrophic health outcomes, including collateral damage to the heart, lungs, and other organ systems, amputations, and death. ...
The procedure was performed safely and easily due to the pump’s position in the aorta versus the heart, which allowed for rapid deployment of the catheter-based pump and significantly reduced the risk of stroke and damage to the heart,” stated Dr. ...
Unfortunately, delays in treatment can lead to a host of catastrophic health outcomes, including collateral damage to the heart, lungs, and other organ systems, amputations, and death. ...
But it wasn’t just dramatic specialties like cancer or heart care that saw collateral damage from COVID. Ophthalmology was hit the hardest of all. ...
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood ...
“COVID-19 has been reported to cause or worsen heart damage, and with the progressive nature of heart failure, delays in treatment can worsen the prognosis for patients. ...
XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. One patient was dosed at The Christ Hospital Health Network and a second at Minneapolis Heart Institute Foundation. ...
XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co-founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize ...
There was a significant reduction of scar tissue in the damaged heart muscle, which conveyed a reduced likelihood of developing heart failure. ...
When the clogged blood vessels are pierced with a fine wire mesh, a large amount of blood is supplied to the stopped heart. In this case, the active oxygen suddenly increases and damages the heart muscle. Bilirubin, which has an antioxidant effect, removes free radicals and minimizes damage to the heart muscle. ...